Skip to main content
. 2022 May 27;42(6):513–524. doi: 10.1007/s40261-022-01156-4
This phase 1 study in healthy adults suggests there is a negligible food effect and no diurnal variation on the bioavailability of trofinetide, an investigational agent for the treatment of Rett syndrome.
Trofinetide was primarily excreted unchanged in urine.